The following 88 NSCLC clinical trials are available to participate in the UK:
A Study of SGN-ALPV in Advanced Solid Tumors (Phase 1, enrolling 285 patients; Interventional)
Study of Pembrolizumab/Vibostolimab Coformulation (MK-7684A) in Combination With Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (MK-7684A-007/KEYVIBE-007) (Phase 3, enrolling 700 patients; Interventional)
A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer (Phase 3, enrolling 999 patients; Interventional)
RBN-2397 in Combination With Pembrolizumab in Patients With SCCL (Phase 1|Phase 2, enrolling 50 patients; Interventional)
A Global Study to Assess the Effects of Osimertinib in Participants With EGFRm Stage IA2-IA3 NSCLC Following Complete Tumour Resection (Phase 3, enrolling 380 patients; Interventional)
A Study of NX-1607 in Adults With Advanced Malignancies (Phase 1, enrolling 336 patients; Interventional)
First-in-human Study of OVM-200 as a Therapeutic Cancer Vaccine (Phase 1, enrolling 36 patients; Interventional)
A Phase III, Open-Label Study of Maintenance Lurbinectedin in Combination With Atezolizumab Compared With Atezolizumab in Participants With Extensive-Stage Small-Cell Lung Cancer (Phase 3, enrolling 690 patients; Interventional)
IO102-IO103 in Combination With Pembrolizumab as First-line Treatment for Patients With Metastatic NSCLC, SCCHN, or mUBC (Phase 2, enrolling 90 patients; Interventional)
HMBD-001 in Advanced HER3 Positive Solid Tumours (Phase 1|Phase 2, enrolling 135 patients; Interventional)
A Study to Learn How Safe the Study Drug BAY 2416964 (AhR Inhibitor) in Combination With the Treatment Pembrolizumab is, How This Combination Affects the Body, the Maximum Amount That Can be Given, How it Moves Into, Through and Out of the Body and Its Action Against Advanced Solid Cancers in Adults (Phase 1, enrolling 78 patients; Interventional)
PD-L1 Expression in Lung Cancer (Phase 2, enrolling 15 patients; Interventional)
Nous-PEV: a Novel Immunotherapy for Lung Cancer and Melanoma (Phase 1, enrolling 34 patients; Interventional)
A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure (Phase 3, enrolling 500 patients; Interventional)
A Study Evaluating the Safety, Pharmacokinetics and Early Efficacy of AVA6000 in Solid Tumours (Phase 1, enrolling 80 patients; Interventional)
A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC) (Phase 3, enrolling 698 patients; Interventional)
A Trial of ChAdOx1 and MVA Vaccines Against MAGE-A3 and NY-ESO-1 (Phase 1|Phase 2, enrolling 86 patients; Interventional)
(SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC (Phase 1|Phase 2, enrolling 190 patients; Interventional)
A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC) (Phase 3, enrolling 170 patients; Interventional)
Phase 3 Study of MRTX849 (Adagrasib) vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation (Phase 3, enrolling 340 patients; Interventional)
A Study of SGN-STNV in Advanced Solid Tumors (Phase 1, enrolling 225 patients; Interventional)
Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer With or Without Actionable Genomic Alterations (TROPION-LUNG01) (Phase 3, enrolling 590 patients; Interventional)
Study of Cobolimab in Combination With Dostarlimab and Docetaxel in Advanced NSCLC Participants (Phase 2|Phase 3, enrolling 250 patients; Interventional)
Atovaquone With Radical ChemorADIotherapy in Locally Advanced NSCLC (Phase 1, enrolling 20 patients; Interventional)
Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies (Phase 1|Phase 2, enrolling 715 patients; Interventional)
Phase III Study to Determine Efficacy of Durvalumab in Stage II-III Non-small Cell Lung Cancer (NSCLC) After Curative Intent Therapy. (Phase 3, enrolling 284 patients; Interventional)
Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013) (Phase 3, enrolling 672 patients; Interventional)
A Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC) (Phase 2, enrolling 520 patients; Interventional)
A Study of Tiragolumab in Combination With Atezolizumab Plus Pemetrexed and Carboplatin/Cisplatin Versus Pembrolizumab Plus Pemetrexed and Carboplatin/Cisplatin in Participants With Previously Untreated Advanced Non-Squamous Non-Small Cell Lung Cancer (Phase 2, enrolling 500 patients; Interventional)
HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer (Phase 2, enrolling 420 patients; Interventional)
A Study of Sasanlimab With Other Therapies in People With Non-small Cell Lung Cancer (Phase 1|Phase 2, enrolling 375 patients; Interventional)
INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid Tumors (Phase 1, enrolling 230 patients; Interventional)
Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations (Phase 2, enrolling 270 patients; Interventional)
Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Solid Tumors Malignancies (Phase 1|Phase 2, enrolling 172 patients; Interventional)
A Platform Study of Novel Agents in Combination With Radiotherapy in NSCLC (Phase 1, enrolling 200 patients; Interventional)
A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions (Phase 3, enrolling 300 patients; Interventional)
A Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Participants With Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC) (Phase 3, enrolling 800 patients; Interventional)
A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (Phase 3, enrolling 1000 patients; Interventional)
Placebo-controlled Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants With Advanced/Metastatic Non-small Cell Lung Cancer (Phase 3, enrolling 650 patients; Interventional)
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation (Phase 1, enrolling 438 patients; Interventional)
A Study of SGN-B6A in Advanced Solid Tumors (Phase 1, enrolling 285 patients; Interventional)
Phase III Study to Determine the Efficacy of Durvalumab in Combination With Chemotherapy in Completely Resected Stage II-III Non-small Cell Lung Cancer (NSCLC) (Phase 3, enrolling 332 patients; Interventional)
Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012) (Phase 3, enrolling 870 patients; Interventional)
Study of Lorlatinib In Participants With Anaplastic Lymphoma Kinase (ALK) -Positive NSCLC (Phase 4, enrolling 85 patients; Interventional)
A Study of Osimertinib With or Without Chemotherapy Versus Chemotherapy Alone as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung Cancer (Phase 3, enrolling 328 patients; Interventional)
eRAPID: Online Symptom Reporting in Lung Cancer (Not Applicable, enrolling 100 patients; Interventional)
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid Tumors (Phase 1, enrolling 100 patients; Interventional)
A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer (Phase 1, enrolling 397 patients; Interventional)
ABC-lung: Atezolizumab, Bevacizumab and Chemotherapy in EGFR-mutant Non-small Cell Lung Carcinoma (Phase 2, enrolling 95 patients; Interventional)
KEBI-Cyto Study - Use of the Biocartis Idylla (Not Applicable, enrolling 200 patients; Interventional)
A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) (Phase 3, enrolling 226 patients; Interventional)
A Study of Selpercatinib (LY3527723) in Participants With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer (Phase 3, enrolling 250 patients; Interventional)
Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression (Phase 1|Phase 2, enrolling 312 patients; Interventional)
Dose Escalation Study of a PD1-LAG3 Bispecific Antibody in Patients With Advanced and/or Metastatic Solid Tumors (Phase 1, enrolling 320 patients; Interventional)
TAK-788 as First-line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations (Phase 3, enrolling 318 patients; Interventional)
Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT411 (Phase 1|Phase 2, enrolling 60 patients; Interventional)
GEN1042 Safety Trial and Anti-tumor Activity in Subjects With Malignant Solid Tumors (Phase 1|Phase 2, enrolling 447 patients; Interventional)
A First-in-Humans Dose Finding Study for an Aryl Hydrocarbon Receptor Inhibitor (AhRi) in Patients With Advanced Cancer (Phase 1, enrolling 141 patients; Interventional)
DS8201a and Pembrolizumab in Participants With Locally Advanced/Metastatic Breast or Non-Small Cell Lung Cancer (Phase 1, enrolling 115 patients; Interventional)
A Study of SGN-CD228A in Advanced Solid Tumors (Phase 1, enrolling 210 patients; Interventional)
ATL001 in Patients With Advanced Unresectable or Metastatic NSCLC (Phase 1|Phase 2, enrolling 50 patients; Interventional)
A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors (Phase 2, enrolling 264 patients; Interventional)
A Study of Nivolumab and Ipilimumab in Untreated Participants With Stage 3 Non-small Cell Lung Cancer (NSCLC) That is Unable or Not Planned to be Removed by Surgery (Phase 3, enrolling 888 patients; Interventional)
A Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Removal and Adjuvant Treatment With Nivolumab or Placebo for Participants With Surgically Removable Early Stage Non-small Cell Lung Cancer (Phase 3, enrolling 452 patients; Interventional)
Efficacy and Safety Study of Stereotactic Body Radiotherapy (SBRT) With or Without Pembrolizumab (MK-3475) in Adults With Unresected Stage I or II Non-Small Cell Lung Cancer (NSCLC) (MK-3475-867/KEYNOTE-867) (Phase 3, enrolling 530 patients; Interventional)
A Trial of BXCL701 and Pembrolizumab in Patients With mCRPC Either Small Cell Neuroendocrine Prostate Cancer or Adenocarcinoma Phenotype. (Phase 1|Phase 2, enrolling 135 patients; Interventional)
A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors (Phase 1|Phase 2, enrolling 100 patients; Interventional)
Durvalumab vs Placebo With Stereotactic Body Radiation Therapy in Early Stage Unresected Non-small Cell Lung Cancer Patients (Phase 3, enrolling 733 patients; Interventional)
Safety and Efficacy of KY1044 and Atezolizumab in Advanced Cancer (Phase 1|Phase 2, enrolling 412 patients; Interventional)
A Study to Investigate Atezolizumab Subcutaneous in Patients With Previously Treated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (Phase 3, enrolling 400 patients; Interventional)
Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors (Phase 2, enrolling 135 patients; Interventional)
Study of ADCT-301 in Patients With Selected Advanced Solid Tumors (Phase 1, enrolling 95 patients; Interventional)
A Phase I/Ib Study of NZV930 Alone and in Combination With PDR001 and /or NIR178 in Patients With Advanced Malignancies. (Phase 1, enrolling 344 patients; Interventional)
PROCLAIM-CX-2029: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2029 for Patients With Solid Tumors or DLBCL (Phase 1|Phase 2, enrolling 150 patients; Interventional)
Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung Cancer (Phase 2, enrolling 310 patients; Interventional)
BT1718 in Patients With Advanced Solid Tumours. (Phase 1|Phase 2, enrolling 130 patients; Interventional)
Assessment of Precision Irradiation in Early NSCLC and Interstitial Lung Disease (Not Applicable, enrolling 39 patients; Interventional)
Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors (Phase 2, enrolling 532 patients; Interventional)
A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer) (Phase 1|Phase 2, enrolling 435 patients; Interventional)
Study Evaluating Safety, Tolerability and PK of AMG 757 in Adults With Small Cell Lung Cancer (Phase 1, enrolling 382 patients; Interventional)
First-in-Human Study of XMT-1536 in Cancers Likely to Express NaPi2b (Phase 1|Phase 2, enrolling 444 patients; Interventional)
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors (Phase 1|Phase 2, enrolling 344 patients; Interventional)
Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON). (Phase 3, enrolling 1193 patients; Interventional)
A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001) (Phase 1|Phase 2, enrolling 989 patients; Interventional)
A CR-UK Phase I Trial of LY3143921 (Phase 1, enrolling 115 patients; Interventional)
A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (Phase 1|Phase 2, enrolling 500 patients; Interventional)
Study of TSR-042, an Anti-programmed Cell Death-1 Receptor (PD-1) Monoclonal Antibody, in Participants With Advanced Solid Tumors (Phase 1, enrolling 740 patients; Interventional)
Study of Amivantamab, a Human Bispecific EGFR and cMet Antibody, in Participants With Advanced Non-Small Cell Lung Cancer (Phase 1, enrolling 780 patients; Interventional)
A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors (Phase 2, enrolling 204 patients; Interventional)
Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions) (Phase 2, enrolling 700 patients; Interventional)
JoLT-Ca Sublobar Resection (SR) Versus Stereotactic Ablative Radiotherapy (SAbR) for Lung Cancer (Phase 3, enrolling 272 patients; Interventional)
Stereotactic Ablative Radiotherapy for Oligometastatic Non-small Cell Lung Cancer (Not Applicable, enrolling 340 patients; Interventional)
Deciphering Antitumour Response and Resistance With INtratumour Heterogeneity (Phase 2, enrolling 119 patients; Interventional)
Hyperpolarized Xenon Gas MR Imaging in NSCLC Radiotherapy (Phase 2, enrolling 50 patients; Interventional)